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Abstract
Background—People with germline mutation in one of the DNA mismatch repair (MMR) genes 
have increased colorectal cancer risk. For these high-risk people, study findings of the relationship 
between alcohol consumption and colorectal cancer risk have been inconclusive.
Methods—1,925 MMR gene mutations carriers recruited into the Colon Cancer Family Registry 
who had completed a questionnaire on lifestyle factors were included. Weighted Cox proportional 
hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals 
(CIs) for the association between alcohol consumption and colorectal cancer.
Results—Colorectal cancer was diagnosed in 769 carriers (40%) at a mean (standard deviation) 
age of 42.6 (10.3) years. Compared with abstention, ethanol consumption from any alcoholic 
beverage up to 14 grams/day and >28 grams/day were associated with increased colorectal cancer 
risk (HR, 1.50; 95%CI, 1.09–2.07 and 1.69; 95%CI, 1.07–2.65 respectively; P-trend=0.05), and 
colon cancer risk (HR, 1.78; 95%CI, 1.27–2.49 and 1.94; 95%CI, 1.19–3.18 respectively; P-
trend=0.02). However, there was no clear evidence for an association with rectal cancer risk. Also, 
there was no evidence for associations between consumption of individual alcoholic beverage 
types (beer, wine, spirits) and colorectal, colon, or rectal cancer risk.
Conclusion—Our data suggests that alcohol consumption, particularly more than 28 grams/day 
of ethanol (~2 standard drinks of alcohol in the US), is associated with increased colorectal cancer 
risk for MMR gene mutation carriers.
Impact—Although these data suggested that alcohol consumption in MMR carriers was 
associated with increased colorectal cancer risk, there was no evidence of a dose-response, and not 
all types of alcohol consumption were associated with increased risk.
Keywords
alcohol consumption; colorectal cancer; mismatch repair; Lynch syndrome
INTRODUCTION
Lynch syndrome, previously known as hereditary non-polyposis colorectal cancer (HNPCC) 
(1), is an autosomal dominant disorder of cancer predisposition caused by heterozygous 
germline mutations in the DNA mismatch repair (MMR) genes, MLH1, MSH2, MSH6, and 
PMS2 or a deletion in EPCAM (2). Approximately 1 in 300 to 370 people in the general 
population carry a mutation in an MMR gene (3, 4). MMR gene mutation carriers are at 
increased risk of colorectal cancer, with an estimated cumulative risk to age 70 years 
between 40% and 70% depending on sex and mutated MMR gene (5–9). Approximately 2–
4% of all colorectal cancers (10, 11) and 10–15% of colorectal cancers diagnosed before age 
50 years (12, 13) can be attributed to Lynch syndrome. Personal and lifestyle factors could 
modify cancer risk for MMR gene mutation carriers (14). Identifying potentially protective 
or harmful risk factors for this high-risk group could assist with reducing their cancer risk, 
as well as understanding carcinogenesis.
For the general population, evidence from systematic reviews and meta-analyses supports a 
positive association between alcohol consumption and colorectal cancer risk, which is likely 
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to be most evident at moderate to high levels of alcohol consumption (15–18). There is little 
evidence that this increased risk differs by alcoholic beverage types, sex, or the site of the 
colorectum (16, 18).
For MMR gene mutation carriers, only a few studies have investigated the association 
between alcohol consumption and colorectal cancer risk and their findings have been 
inconclusive (19–21). All these studies had small sample sizes, different selection criteria for 
participants (confirmed mutation carriers, those who met clinical criteria for HNPCC), 
different outcome measures (colorectal cancer, polyps, or both), and none investigated the 
association between lifetime alcohol consumption and colorectal cancer risk.
In this study, we estimated the associations between lifetime alcohol consumption and 
colorectal cancer risk for MMR gene mutation carriers using a large dataset from the Colon 
Cancer Family Registry. We also estimated the associations separately for different beverage 
types, for colon and rectal cancers, and for men and women.
MATERIALS AND METHODS
Study Sample
This study involved carriers of heterozygous germline pathogenic mutations in MMR genes 
who had been recruited by the Colon Cancer Family Registry. Detailed descriptions of study 
design and recruitment have been published (22) and are available at http://coloncfr.org (22). 
Between 1997 and 2012, the Colon Cancer Family Registry recruited and interviewed 
probands who were either recently diagnosed with colorectal cancer that was reported to 
state or regional population cancer registries in the United States (Washington, California, 
Arizona, Minnesota, Colorado, New Hampshire, North Carolina, and Hawaii), Australia 
(Victoria), and Canada (Ontario); or were from multiple-case families referred to family-
cancer clinics in the United States (Mayo Clinic, Rochester, Minnesota; and Cleveland 
Clinic, Cleveland, Ohio), Australia (Melbourne, Adelaide, Perth, Brisbane, and Sydney), 
Canada (Ontario), and New Zealand (Auckland). Permission was obtained from probands to 
contact their affected and unaffected relatives and seek their enrolment in the Colon Cancer 
Family Registry. For families recruited via population-based registries, first-degree relatives 
of probands were recruited by all centers. Recruitment was extended to more distant 
relatives by some centers. For families recruited via family-cancer clinics, attempts were 
made to recruit also second-degree relatives of affected individuals (details provided by 
Newcomb et al. (22)). Informed consent was obtained from all participants and the study 
protocol was approved by research ethics review board at each recruitment center.
Data Collection
At the time of baseline recruitment, standardized questionnaires were used to collect self-
reported information on demographics, lifestyle factors including alcohol consumption, 
personal and family history of cancer, cancer-screening history, and history of polyps, 
polypectomy, and other surgeries from all participants via personal interviews, telephone 
interviews, or mailed questionnaires. The questionnaires used by the Colon Cancer Family 
Registry centers are available at http://coloncfr.org/questionnaires. Pathology reports, 
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medical records, cancer registry reports, and death certificates were consulted, when 
possible, to confirm reported cancer diagnoses and age at diagnosis. Attempts were made to 
obtain blood samples from all participants and tumor tissue samples from all colorectal-
cancer-affected participants.
MMR Gene Mutation Testing
Testing for germline mutations in MLH1, MSH2, MSH6, and PMS2 was performed for all 
population-based probands who had a colorectal tumor that showed impaired MMR 
function, as evidenced by tumor microsatellite instability (MSI) or absence of MMR-protein 
expression in immunohistochemical analysis. Testing was also performed for the colorectal-
cancer-affected participants from clinic-based families regardless of tumor MSI or MMR-
protein expression status. Sanger sequencing or denaturing high performance liquid 
chromatography, followed by confirmatory DNA sequencing, was performed to screen for 
mutations in the MLH1, MSH2, and MSH6 genes. Large duplication and deletion mutations 
were detected by Multiplex Ligation Dependent Probe Amplification (MLPA) according to 
the manufacturer’s instructions (MRC Holland, Amsterdam, the Netherlands) (22–24). 
PMS2 mutation testing involved a modified protocol from Senter et al (7), in which exons 1 
to 5, 9, and 11 to 15 were amplified with 3 long-range polymerase chain reactions (PCRs) 
followed by nested exon-specific PCR and sequencing. The remaining exons (7, 8, and 10) 
were amplified and sequenced directly from genomic DNA. Large-scale deletions in PMS2 
were detected using the P008-A1 MLPHA kit (MRC Holland, Amsterdam, the Netherlands) 
(25). Relatives of probands with a pathogenic MMR germline mutation (26) who provided a 
blood sample were tested for the specific mutation identified in the proband.
Definitions of Exposure and Outcome
The primary outcome was self-reported diagnosis of colorectal cancer. The primary 
exposure was grams of ethanol consumption per day from alcoholic beverages from age 20 
years to age at colorectal cancer diagnosis or age at censoring.
At baseline, participants were asked to report the number of 12-oz servings of beer or 
alcoholic cider (included as beer in the remainder of this paper), 4-oz servings of wine or 1-
oz servings of sake (included as wine), and 1-oz servings of spirits that they had consumed 
daily or weekly in their 20s, 30s and 40s, and 50s and older, as well as the number of years 
they had consumed the alcoholic beverages at least once a week for 6 months or longer 
during each of these periods.
Grams of ethanol in alcoholic beverages (14 grams in 12-oz serving of beer, 11.2 grams in 4-
oz serving of wine, 3.5 grams in 1-oz serving of sake, and 9.3 grams in 1-oz serving of 
spirits) were calculated based on average alcohol content in each drink (5% in beer, 12% in 
wine, 15% in sake, and 40% in spirits), density of ethanol (0.79 grams/ml), and converting 
US/British Imperial measurements of volume to metric (1 oz. equivalent to 29.57 ml).
Grams of ethanol consumption per day from alcoholic beverages when drinking beer, wine, 
and spirits were calculated based on self-reported number of alcoholic beverages consumed 
and years of alcohol consumption from age 20 years to age at colorectal cancer diagnosis or 
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age at censoring. Abstainers were defined as carriers who had not consumed alcohol for at 
least once a week for 6 months or longer throughout this period.
Statistical Analysis
Cox proportional regression analyses, with age as the time scale, were used to estimate the 
association between alcohol consumption and the risk of colorectal cancer for MMR gene 
mutation carriers. Time at risk started at age 20 years and ended at age of first colorectal 
cancer diagnosis, any other cancer diagnosis, polypectomy, or age at baseline interview, 
whichever occurred first. Observation time ended at age of diagnosis of any other cancer, 
because subsequent cancer treatment and surveillance could have altered later colorectal 
cancer risk and MMR gene mutations carriers might have changed their behavior following 
cancer diagnosis.
Because colorectal cancer cases from multiple-cancer families and cases with early-onset 
colorectal cancer were preferentially tested for MMR gene mutations, selection of carriers 
was not random with respect to their disease status. This non-random ascertainment was 
adjusted for in the analysis by applying probability weights to carriers based on the weighted 
cohort approach developed by Antoniou et al. (27). Age-specific incidences of colorectal 
cancer for MMR gene mutation carriers (28) were used to calculate statistical weights for 
colorectal-cancer-affected and -unaffected carriers for each age-stratum so the proportion of 
affected carriers in each age-stratum was equal to the proportion of affected carriers in the 
general population.
Variables that were considered as potential confounders are listed in Table 1. When 
applicable, all variables, including the alcohol consumption variables, were treated as time-
varying covariates. We were not able to generate time-varying variables for consumption of 
aspirin or ibuprofen, and multivitamin, calcium, and folic acid supplements because we did 
not have information on carriers’ age at first exposure to regular consumption of these 
medications and supplements. For investigating the associations between consumption of 
specific types of alcoholic beverages with colorectal cancer risk, after confirming that these 
variables were not strongly correlated (all correlation coefficients were ≤0.25) and running 
collinearity diagnostic tests, consumption of the other two sources of ethanol were included 
as potential confounders in the multivariable models. The proportional hazards assumption 
was tested with the Schoenfeld and scaled Schoenfeld residuals (29). The confounding 
variables that did not meet the proportional hazards assumption were stratified for in the 
final models. The overall model fit was assessed using Cox-Snell residuals as the time 
variable and plotting them against the Nelson-Aalen cumulative hazard function (30). For 
continuous variables, deviation from linearity was tested using the likelihood ratio test in 
comparison between models with the original variable and models that included the original 
and quadric transformation of the variable. To test for interaction, the difference in the log-
likelihood ratio was assessed after adding a cross-product term between each exposure 
variable and the potential effect modifiers identified a priori. The numbers of missing values 
for all variables are reported in Tables 1 to 2. All univariable analyses were complete case 
analyses. In the multivariable models, all confounder variables were fitted as categorical 
variables with their missing values (all <8%) coded as an additional category.
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We estimated associations by each colorectal cancer site, sex and cancer site, smoking 
status, body mass index (BMI) at age 20 years, and history of having received 
sigmoidoscopy or colonoscopy. The following additional analyses were also conducted: 
analyses with colorectal polyp or cancer as the outcome; and analyses restricted to carriers 
who received a colorectal cancer diagnosis or were censored within 5 years before interview 
to reduce survival bias. To take into account the potential correlation in risk between family-
members, we used the Huber-White robust variance estimation by clustering on family 
membership (31, 32). All statistical tests were two-sided. All statistical analyses were 
performed using STATA statistical software, version 13.0 (Stata Corp LP, College Station, 
Texas, USA).
RESULTS
A total of 2,031 MMR gene mutation carriers were identified from the Colon Cancer Family 
Registry. Of these, the 53 (2.6%) who were younger than 20 years old at the time of 
colorectal cancer diagnosis (n=11) or censoring (n=42) were excluded. We also excluded 16 
colorectal cancer-affected and 36 unaffected carriers for whom no data on alcohol 
consumption were available, and one carrier whose reported average ethanol consumption 
from alcoholic beverages was more than 200 grams per day. Excluded carriers had similar 
characteristics compared to those who were included in this study (details not shown).
The final sample comprised 1,925 MMR gene mutation carriers (920 were recruited as 
colorectal affected cases and 1005 as unaffected) from 761 families. Of these, 1,077 (56%) 
were female; 1,425 (74%) were recruited through family-cancer clinics; and 714 carried a 
mutation in MLH1, 898 in MSH2, 215 in MSH6, and 98 in PMS2. Time at risk ended at age 
at colorectal cancer diagnosis for 769 carriers (643 located in the colon, 116 in the rectum, 
and 10 in both the colon and rectum), polypectomy for 338, other cancer diagnosis for 224, 
and interview for 594. The time interval (standard deviation, SD) between age at colorectal 
cancer diagnosis and age at interview for affected carriers was 9.1 (9.8) years, and between 
censored age and age at interview for unaffected carriers was 5.1 (8.8) years (P=0.20). 
Colorectal cancer incidence from age 20 was 1.8 (95% confidence interval (CI), 1.68 – 1.93) 
per 100 person-years and mean (SD) age at diagnosis was 42.6 (10.3) years. Colorectal 
cancer diagnosis was confirmed for 704 affected carriers (92%) by pathology reviews or 
reports, cancer registries, or hospital records.
Characteristics of MMR gene mutation carriers included in the present study are 
summarized in Table 1. On average, men had higher consumption of ethanol from any 
alcoholic beverage than women (mean (SD) in unaffected carriers: 15.9 (21.1) vs. 4.2 (9.6) 
grams per day) as well as from beer and spirits. Average ethanol consumption per day from 
any alcoholic beverage and from beer were higher in colorectal cancer-affected carriers 
compared with unaffected carriers (12.9 (21.4) vs. 8.6 (16.0) grams per day and 8.7 (19.3) 
vs. 4.9 (11.1) grams per day, respectively) (Table 2).
Compared with abstention, consumption of ethanol from any alcoholic beverage both up to 
14 grams/day and >28 grams/day were associated with an increased risk of colorectal cancer 
(HR, 1.50; 95% CI, 1.09 – 2.07 and 1.69; 95% CI, 1.07 – 2.65 respectively). There was 
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evidence for a linear dose-dependent relationship between ethanol intake from any alcoholic 
beverage and colorectal cancer risk in the univariable model (HR per 14 grams/day, 1.07; 
95% CI, 1.01 – 1.14), but not in the multivariable model (HR per 14 grams/day, 1.02; 95% 
CI, 0.94 – 1.09). Similarly, there were associations between beer and spirit consumption and 
colorectal cancer risk in the univariable models, but no clear association between the 
consumption of any alcohol type (beer, wine or spirits) and colorectal cancer risk in the 
multivariable models (Table 3).
An increased risk of colon, but not rectal, cancer was associated with ethanol consumption 
from any alcoholic beverage of up to 14 grams/day (HR, 1.78; 95% CI, 1.27 – 2.49) and >28 
grams/day (HR, 1.94; 95% CI, 1.19 – 3.18) in multivariable models (Table 4). Similar 
results were seen in analyses when the outcome was defined as colorectal polyp or cancer 
(HR for ethanol >28 grams/day vs. abstention, 1.46; 95% CI, 1.15 – 1.86) (Supplementary 
Table 1), and in analyses restricted to carriers who were diagnosed with colorectal cancer or 
censored within 5 years before interview (HR for ethanol >28 grams/day vs. abstention, 
1.29; 95% CI, 0.65 – 2.53) (Supplementary Table 2).
There was no evidence for an interaction between alcohol consumption and sex (P=0.78; 
Figure 1), cigarette smoking status (P=0.61), BMI at age 20 (P=0.88), history of having 
received sigmoidoscopy or colonoscopy (P=0.43) (Supplementary Table 3), the specific 
mutated MMR gene (P=0.99), country of recruitment (P=0.99), ascertainment method 
(P=0.11), or folic acid supplement intake (P=0.37) (Supplementary Table 4). There was no 
evidence of non-linearity for continuous variables, or of violation of the proportional hazards 
assumption by any of the main alcohol variables in any of the final models. The unweighted 
and weighted analyses yielded similar results, although the weighted analyses gave larger 
standard errors and wider confidence intervals (details not shown).
DISCUSSION
We found that alcohol consumption particularly more than 28 grams/day of ethanol (~2 
standard drinks of alcohol in the US) was associated with an increased risk of colorectal 
cancer for MMR gene mutation carriers. The direction and strength of associations that we 
estimated for carriers were similar to those reported by a meta-analysis of 7 studies on 
associations between long-term alcohol consumption and colorectal cancer (relative risk for 
highest vs. lowest category, 1.49; 95% CI, 1.27 – 1.74) (15), and meta-analyses of 
associations between current alcohol consumption and colorectal cancer risk (17, 18, 33), 
estimated for the general population. For the general population, alcohol consumption has 
been reported to increase the risk of both colon and rectal cancer (16, 18). In this study, 
however, we did not find evidence for a positive association between alcohol consumption 
and rectal cancer. While our overall results were not contrary to findings for the general 
population (16) (95% CIs were compatible), the small number of rectal cancer cases with 
available data on alcohol consumption (n=104) could possibly explain the lack of evidence 
for an association between alcohol consumption and rectal cancer in our study (in MMR 
gene mutation carriers, proximal colon is the predominant site for colorectal cancers (34)). 
Similarly, our study provided no clear evidence for an association between individual 
beverage types and colorectal, colon, or cancer risk and in separate analyses for men and 
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women. This might be due to limited statistical power given the limits of confidence 
intervals for estimates from these sub-analyses. The reason for absence of a clear dose-
dependent relationship between alcohol consumption and colorectal cancer risk in our study 
is not clear. However, in part, it might be because the majority of this cohort (n=831) were 
light alcohol drinkers (0 to 14 grams per day), a limited number of carriers (n=188; 16 
women and 172 men) were in our highest category of alcohol consumption (more than 28 
grams per day), and our study was under powered to assess dose-dependent relationship, 
particularly at high levels of alcohol consumption.
A few previous studies have investigated the association between alcohol consumption and 
the risk of colorectal cancer (19), colorectal polyp or cancer (20), and colorectal adenoma 
(21), for MMR gene mutation carriers. In a retrospective cohort study of 271 MMR gene 
mutation carriers, Watson et al. reported no evidence for an association between alcohol use 
and colorectal cancer risk (P>0.4; estimates not reported) (19). In a Dutch case-control study 
of suspected and confirmed MMR gene mutation carriers (145 cases with colorectal cancer 
(n=36) or polyps (n=119) vs. 103 controls), Diergaarde et al. did not find evidence for an 
association between alcohol consumption and the risk of colorectal polyp or cancer (odds 
ratio ≥12.8 grams/day vs. ≤2.6 grams/day, 1.0; 95% CI 0.5 – 2.0) (20). However, as here, 
those authors reported greater alcohol consumption by cases than controls (mean (SD) 14.0 
(15.2) vs. 9.8 (10.9)) (20). In a prospective cohort study of 386 MMR gene mutation carriers 
(58 diagnosed with colorectal adenoma over a median follow-up of 10 months), Winkels et 
al. reported an HR of 1.56 (95% CI, 0.71 – 3.43) for the association between highest vs. 
lowest tertiles of alcohol consumption and the risk of colorectal adenoma. This is similar to 
our estimate from analysis in which the outcome was defined as either colorectal polyp or 
cancer (HR >28 grams/day vs. abstention, 1.60; 95% CI, 1.16 – 2.20) (21). The smaller 
sample sizes of those studies relative to ours could explain their lack of evidence for 
associations between alcohol consumption and the risk of colorectal polyp or cancer.
The mechanisms of alcohol-related carcinogenesis specifically for MMR gene mutation 
carriers are not known. For the general population, it has been suggested that acetaldehyde, a 
metabolite of ethanol found in high concentrations in the colon following alcohol 
consumption, has a carcinogenic role. Acetaldehyde affects DNA synthesis and repair, alters 
the structure and function of glutathione (an anti-oxidative peptide), and increases mucosal 
proliferation in the colon (35). There is also evidence that ethanol could have carcinogenic 
effects by altering methyl group transfer (35).
To the best of our knowledge, this is the largest study to date examining the association 
between alcohol consumption and colorectal cancer risk for MMR gene mutation carriers. 
Data for this study came from the Colon Cancer Family Registry, which used standardized 
and uniform questionnaires and conducted standardized genetic screening for MMR gene 
mutations (22). To handle the fact that selection of carriers was on the basis of their disease 
status, we used a weighted cohort analyses to produce unbiased estimates (27).
One of the limitations of our study is potential for imprecision in estimates, and attenuation 
toward the null due to non-differential errors in the measurement of alcohol consumption 
and other variables because they were based on self-reported questionnaires. In addition, the 
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assumptions that underpinned our calculation of average alcohol consumption between the 
age of 20 years and age at colorectal cancer diagnosis or censored age might have 
overestimated alcohol consumption for both colorectal affected and unaffected MMR gene 
mutation carriers. Because affected carriers were interviewed after having been diagnosed 
with colorectal cancer, disease status might have influenced their recall of exposures, 
introducing recall bias. Additionally, there may have been residual confounding by factors 
that we were not able to take into account in our analyses. BMI is a known risk factor for 
colorectal cancer (36) and might have confounded the association between alcohol 
consumption and colorectal cancer. We were not able to adjust for recent BMI because this 
variable was available for only 50% of carriers in this study. Because we did not have data 
on age at first regular consumption of aspirin or ibuprofen, or of multivitamin, calcium, and 
folic acid supplements, we were not able to treat them as time-varying variables in our 
analyses. When included as time-fixed variables in the models, the strength and direction of 
estimated alcohol associations did not change. Finally, survival bias might have influenced 
our analysis as affected carriers with better survival were more likely to have been recruited 
into the Colon Cancer Family Registry. However, a supplementary analysis limited to 
carriers who were censored or diagnosed with colorectal cancer within 5 years before the 
interview gave similar results to our main analysis.
For MMR gene mutation carriers, alcohol consumption, particularly more than 28 grams per 
day of ethanol, was associated with an increased risk of colorectal cancer. However, there 
was no clear evidence for a dose-dependent relationship or increased risks associated with 
individual beverage types. These findings need further confirmation, particularly using large 
prospective cohort studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hazard ratios for associations between alcohol consumption and the risk of colon, 
rectum, and colorectal cancer for DNA mismatch repair gene germline mutation carriers by sex
Abbreviations: HR, hazard ratio; CI, confidence interval; PY, person-years
All models were multivariable and adjusted for country (categorical, time-fixed), education 
(categorical, time-fixed l), ascertainment (binary, time-fixed), at age 20 (categorical, time-
fixed), diabetes status (binary, time-varying), regular physical activity (binary, time-varying), 
and smoking status (categorical, time-varying)
Models for women were additionally adjusted for number of live births (categorical, time-
varying), and years of hormonal contraceptive use (categorical, time-varying)
Models for beer were additionally adjusted for average daily ethanol intake from wine 
(binary, time-varying) and from spirits (binary, time-varying)
Models for wine were additionally adjusted for average daily ethanol intake from beer 
(binary, time-varying) and from spirits (binary, time-varying)
Models for sake were additionally adjusted for average daily ethanol intake from beer 
(binary, time-varying) and from wine (binary, time-varying)
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Table 1
Characteristics* of DNA mismatch repair gene germline mutation carriers
No colorectal cancer
N = 1,156 (60%)
Colorectal cancer
N = 769 (40%)
Total
N = 1,925
Sex
 Female 725 (62.7) 352 (45.8) 1,077 (56.0)
 Male 431 (37.3) 417 (54.2) 848 (44.1)
Study Centers, n (%)
 Australia or New Zealand 670 (58.0) 365 (47.5) 1,035 (53.8)
 USA 326 (28.2) 286 (37.2) 612 (31.8)
 Canada 160 (13.8) 118 (15.3) 278 (14.4)
Race
 Caucasian 1,093 (94.6) 693 (90.1) 1,786 (92.8)
 Other 41 (3.6) 64 (8.3) 105 (5.5)
 Missing 22 (1.9) 12 (1.6) 34 (1.8)
Ascertainment method
 Clinic 915 (79.2) 510 (66.3) 1,425 (74.0)
 Population 241 (20.9) 259 (33.7) 500 (26.0)
Age (year),a
 mean (SD) 41.9 (12.8) 42.6 (10.3) 42.2 (11.9)
 median [range] 41 [20 – 85] 43 [20 – 75] 42 [20 – 85]
Year of Birth, n (%)
 1914–1945 256 (22.2) 234 (30.4) 490 (25.5)
 1946–1955 283 (24.5) 234 (30.4) 517 (26.9)
 1956–1965 259 (22.4) 192 (25.0) 451 (23.4)
 1966–1990 258 (31.0) 109 (14.2) 467 (24.3)
Education level, n (%)
 Some high school or less 237 (20.5) 180 (23.4) 417 (21.7)
 Completed high school/some tertiary study 387 (33.5) 259 (33.7) 646 (33.6)
 Vocational/technical school 209 (18.1) 127 (16.5) 336 (17.5)
 University degree 318 (27.5) 196 (25.5) 514 (26.7)
 Missing 5 (0.4) 7 (0.9) 12 (0.6)
Mismatch repair gene mutated, n (%)
 MLH1 381 (33.0) 333 (43.3) 714 (37.1)
 MSH2 571 (49.4) 327 (42.5) 898 (46.7)
 MSH6 151 (13.1) 64 (8.3) 215 (11.2)
 PMS2 53 (4.6) 45 (5.9) 98 (5.1)
BMI at age 20,b n (%)
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No colorectal cancer
N = 1,156 (60%)
Colorectal cancer
N = 769 (40%)
Total
N = 1,925
 Normal 788 (68.2) 489 (63.6) 1,277 (66.3)
 Overweight 183 (15.8) 149 (19.4) 332 (17.3)
 Obese 46 (4.0) 42 (5.5) 88 (4.6)
 Underweight 101 (8.7) 61 (7.9) 162 (8.4)
 Missing 38 (3.3) 28 (3.6) 66 (3.4)
BMI 2 years before diagnosed/censored age,b,c n (%)
 Normal 338 (29.2) 91 (11.8) 429 (22.3)
 Overweight 224 (19.4) 114 (14.8) 338 (17.6)
 Obese 113 (9.8) 60 (7.8) 173 (9.0)
 Underweight 21 (1.8) 7 (0.9) 28 (1.5)
 Missing 460 (39.8) 497 (64.6) 957 (49.7)
Number of received sigmoidoscopy or colonoscopy, n (%)
 0 380 (32.9) 185 (24.1) 565 (29.4)
 1 266 (23.0) 227 (29.5) 493 (25.6)
 2 128 (11.1) 31 (4.0) 159 (8.3)
 3 or more 138 (11.9) 49 (6.4) 187 (9.7)
 Missing 244 (21.1) 277 (36.0) 521 (27.1)
Diabetes, n (%)
 No 1,117 (96.6) 727 (94.5) 1,844 (95.8)
 Yes 33 (2.9) 34 (4.4) 67 (3.5)
 Missing 6 (0.5) 8 (1.0) 14 (0.7)
*
at the time of colorectal cancer diagnosis or age of another cancer, or polypectomy, or interview for colorectal cancer-unaffected participants 
(whichever came first)
aAge of diagnosis of colorectal cancer for affected participants; age of diagnosis of another cancer or polypectomy or interview for colorectal 
cancer-unaffected participants (whichever came first)
b
Body mass index (BMI) calculated as weight in kilograms divided by height in meters squared. Underweight (<18.5), normal (18.5 – 24.9), 
overweight (25.0 – 29.9), obese (≥30)
cCarriers who were diagnosed with colorectal cancer or censored more than 2 years before interview had missing for this variable
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Table 1
Characteristics* of DNA mismatch repair gene germline mutation carriers – continued
No colorectal cancer
N = 1,156 (60%)
Colorectal cancer
N = 769 (40%)
Total
N = 1,925
Aspirin and/or ibuprofen intake,a n (%)
 <1 month 903 (78.1) 632 (82.2) 1,535 (79.7)
 ≥1 month 190 (16.4) 95 (12.4) 285 (14.8)
 Missing 63 (5.5) 42 (5.5) 105 (5.5)
Multivitamin supplement intake,a n (%)
 <1 month 789 (68.3) 584 (75.9) 1,373 (71.3)
 ≥1 month 309 (26.7) 141 (18.3) 450 (23.4)
 Missing 58 (5.0) 44 (5.7) 102 (5.3)
Calcium supplement intake,a n (%)
 <1 month 991 (85.7) 702 (91.3) 1,693 (88.0)
 ≥1 month 121 (10.5) 48 (6.2) 169 (8.8)
 Missing 44 (3.8) 19 (2.5) 63 (3.3)
Folic acid supplement intake,a n (%)
 <1 month 1,012 (87.5) 709 (92.2) 1,721 (89.4)
 ≥1 month 112 (9.7) 39 (5.1) 151 (7.8)
 Missing 32 (2.8) 21 (2.7) 53 (2.8)
Cigarette smoking,b n (%)
 Never 624 (54.0) 345 (44.9) 969 (50.3)
 Former 262 (22.7) 160 (20.8) 422 (21.9)
 Current 267 (23.1) 262 (34.1) 529 (27.5)
 Missing 3 (0.3) 2 (0.3) 5 (0.3)
Regular physical activity,c n (%)
 <3 months 51 (4.4) 47 (6.1) 98 (5.1)
 ≥3 months 1,074 (92.9) 691 (89.9) 1,765 (91.7)
 Missing 31 (2.7) 31 (4.0) 62 (3.2)
Fruit and vegetable intake (servings/day) 2 years before diagnosed/censored 
age,d,e n (%)
 <2 190 (16.4) 111 (14.4) 301 (15.6)
 2.01 – 3 129 (11.2) 45 (5.9) 174 (9.0)
 3.01 – 4 134 (11.6) 47 (6.1) 181 (9.4)
 ≥4.01 256 (22.2) 67 (8.7) 323 (16.8)
 Missing 447 (38.7) 499 (64.9) 946 (49.1)
Red meat intake (servings/day 2 years before diagnosed/censored age),e,f n (%)
 <0.30 211 (18.3) 88 (11.4) 299 (15.5)
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No colorectal cancer
N = 1,156 (60%)
Colorectal cancer
N = 769 (40%)
Total
N = 1,925
 0.31 – 0.60 240 (20.8) 83 (10.8) 323 (16.8)
 0.61 – 0.90 102 (8.8) 45 (5.9) 147 (7.6)
 ≥0.91 or more 153 (13.2) 55 (7.2) 208 (10.8)
 Missing 450 (38.9) 498 (64.8) 948 (49.3)
Number of live births,g n (%)
 No 198 (27.3) 66 (18.8) 264 (24.5)
 1 76 (10.5) 51 (14.5) 127 (11.8)
 2 204 (28.1) 96 (27.3) 300 (27.9)
 ≥3 227 (31.3) 126 (35.8) 353 (32.8)
 Missing 20 (2.8) 13 (3.7) 33(3.1)
Hormonal contraception use,g n (%)
 <1 year 187 (25.8) 100 (28.4) 287 (26.7)
 ≥1 year 527 (72.7) 240 (68.2) 767 (71.2)
 Missing 11 (1.5) 12 (3.4) 23 (2.1)
Menopause status,g n (%)
 Pre-menopause 481 (66.3) 230 (65.3) 711 (66.0)
 Pre-menopause 213 (29.3) 112 (31.9) 325 (30.2)
 Missing 31 (4.3) 10 (2.8) 41 (3.8)
*
at the time of colorectal cancer diagnosis or age of another cancer, or polypectomy, or interview for colorectal cancer-unaffected participants 
(whichever came first)
aAt least twice a week
b
Former smokers defined as carriers who had smoked at least 1 cigarette per day for at least 3 months and had quit more than 2 years before age at 
colorectal cancer or censored age; current smokers defined as carriers who had smoked at least 1 cigarette per day for at least 3 months and 
continued within 2 years of age at colorectal cancer or censored age
c
Regular physical activity defined as any physical activity for at least 30 minutes per week for at least 3 months
dA serving of fruit defined as 1 medium fresh fruit, or ½ cup of chopped, cooked, or canned fruit, or ¼ cup of dried fruit, or 6 ounce of fruit juice; a 
serving of vegetable defined as 1 cup raw leafy vegetables, or ½ cup of other vegetables, or cooked or chopped raw, 6 ounces of vegetable juice
eCarriers who were diagnosed with colorectal cancer or censored more than 2 years before interview had missing for this variable
fA serving of red meat defined as 2–3 ounces of red meat, or a piece of meat about the size of a deck of cards
g
Limited to women (725 unaffected and 352 colorectal cancer affected)
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